Black Diamond Therapeutics, a clinical-stage oncology company, is set to unveil initial Phase 2 clinical trial data for BDTX-1535 in patients with recurrent EGFR-mutated non-small cell lung cancer (NSCLC). The presentation will be webcasted on Monday, September 23, 2024, at 8:00 a.m. ET.
BDTX-1535 is a brain-penetrant, fourth-generation EGFR MasterKey inhibitor designed to target EGFR mutant NSCLC and glioblastoma (GBM). Black Diamond Therapeutics specializes in developing MasterKey therapies that address families of oncogenic mutations, aiming to overcome resistance, minimize wild-type mediated toxicities, and penetrate the central nervous system to treat CNS diseases.
The webcast will be accessible via the “Events and Presentations” section of Black Diamond’s website. A replay will be available following the live presentation.
About BDTX-1535 and EGFRm NSCLC
BDTX-1535 represents a novel approach to targeting EGFR mutations in NSCLC, particularly in cases of recurrence. NSCLC is the most common type of lung cancer, and EGFR mutations are present in a significant subset of these tumors. These mutations often lead to initial sensitivity to first- and second-generation EGFR inhibitors, but resistance inevitably develops. Fourth-generation inhibitors like BDTX-1535 are designed to overcome this resistance, especially in cases where the cancer has metastasized to the brain.
Black Diamond's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors. By targeting families of oncogenic mutations, these therapies aim to provide a more comprehensive and durable response compared to traditional targeted therapies.
Black Diamond's Pipeline
In addition to BDTX-1535, Black Diamond is also advancing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors. Both BDTX-1535 and BDTX-4933 are currently in clinical development.
